Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Summary

The purpose of this study is to evaluate the efficacy and safety of GSK233705B compared with placebo in subjects with COPD.

Timeline

Start

2008-05-16

Primary completion

2008-12-22

Completion

2008-12-22

Outcome

Met primary endpoint

registry analysis (superiority test); GSK233705B 200 mcg vs Placebo; p <0.001; Mean Difference (Net) 0.137 (95% CI 0.086 to 0.187) NCT00676052 ↗

paper Treatment with GSK233705 produced statistically significant improvements in pulmonary function compared with placebo. PMID 22329914 ↗

Publications

• Bateman E, Feldman G, Kilbride S, Brooks J, Mehta R, Harris S, Maden C, Crater G. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD. Clin Respir J. 2012 Oct;6(4):248-57. doi: 10.1111/j.1752-699X.2011.00278.x. Epub 2012 Feb 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	DAROTROPIUM	Small molecule	12.5 ug	Inhaled
Subject	DAROTROPIUM	Small molecule	25 ug	Inhaled
Subject	DAROTROPIUM	Small molecule	50 ug	Inhaled
Subject	DAROTROPIUM	Small molecule	100 ug	Inhaled
Subject	DAROTROPIUM	Small molecule	200 ug	Inhaled

Indications